The resurgence of interest in psychedelic-assisted therapies (PATs) for mental health conditions, such as depression and PTSD, presents a transformative, yet expensive, new treatment avenue. Clinical trials have demonstrated significant therapeutic potential, but the current high out-of-pocket costs pose a significant barrier to equitable access. This commentary argues for the urgent need for comprehensive economic evaluation and cost-effectiveness research in PATs including comparisons to current standards of care. Preliminary cost-effectiveness models are promising, suggesting that while PATs have high initial costs (estimated at $2,000 to over $11,500 per course), they offer potential long-term savings due to self-limited treatment courses and high durability of effects. To validate these models, future research must systematically collect robust real-world data on intervention costs (personnel, drug, facility, etc.), long-term health outcomes (QALYs, remission rates), and broader societal costs and benefits (productivity gains, reduced healthcare utilization). Key opportunities to refine cost-effective delivery include group therapy models and leveraging state-regulated programs (like those in Oregon and Colorado) to conduct impact-focused implementation research more rapidly and less expensively than the conventional FDA-track. This concerted effort is essential to realize the full potential of PATs and ensure their integration into mainstream mental healthcare.